0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      On the Half Life of Thyrotropin-Releasing Hormone in Rats

      ,

      Neuroendocrinology

      S. Karger AG

      Thyrotropin-releasing hormone (TRH), Labeled TRH, half life, Metabolites of TRH

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          After the injection of <sup>14</sup>C-labeled TRH into normal male rats, radioactivity disappeared rapidly from the circulation. The half life of <sup>14</sup>C-TRH was found to be 4.16 min; however, the true half life of TRH may be masked, since TRH is rapidly inactivated in the blood to compounds having similar chemical structures and probably similar half lives. Chromatography of methanol extracts of plasma samples taken at 1, 2, and 6 min revealed that some of the radioactivity had the same R<sub>f</sub> value as that of TRH, while other areas corresponded to the free acid of TRH (pyro-glu-his-pro-OH), glu-his-pro, and his-pro-NH<sub>2</sub>. The mean volume of distribution of TRH in our studies was 18.5% of the body weight. Approximately 25% of the radioactivity was excreted into the urine within 60 min after the intravenous injection of 1 µCi of <sup>14</sup>C-TRH. Urinary radioactive metabolites appeared to have the same electrophoretic mobilities as TRH and the free acid of TRH.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1972
          1972
          19 March 2008
          : 9
          : 4
          : 250-256
          Affiliations
          Endocrine and Polypeptide Laboratories, Veterans Administration Hospital and Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana
          Article
          122056 Neuroendocrinology 1972;9:250–256
          10.1159/000122056
          4622720
          © 1972 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Paper

          Comments

          Comment on this article